Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma.
Ding X, Huang T, Peng C, Ahn KS, Andersen JB, Lewinska M, Cao Y, Xu G, Chen G, Kong B, Friess H, Shen S, Roberts LR, Wang L, Zou X.
J Cancer
11 :
2020
2241-2251
2
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabró R, Pinyol R, Torres-Martin M, Bassaganyas L, Moeini A, Peix J, Cabellos L, Maeda M, Villacorta-Martin C, Tabrizian P, Rodriguez-Carunchio L, Castellano G, Sempoux C, Minguez B, Pawlik TM, Labgaa I, Roberts LR, Sole M, Fiel MI, Thung S, Fuster J, Roayaie S, Villanueva A, Schwartz M, Llovet JM.
J Hepatol
73 :
2020
315-327
156
Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities.
Dinh TA, Sritharan R, Smith FD, Francisco AB, Ma RK, Bunaciu RP, Kanke M, Danko CG, Massa AP, Scott JD, Sethupathy P.
Cell Rep
31 :
2020
107509
29
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L, Alvarez-Sola G, Latasa MU, Uriarte I, Herranz JM, Arechederra M, Vlachogiannis G, Rae C, Pineda-Lucena A, Casadei-Gardini A, Pedica F, Aldrighetti L, López-López A, López-Gonzálvez A, Barbas C, Ciordia S, Van Liempd SM, Falcón-Pérez JM, Urman J, Sangro B, Vicent S, Iraburu MJ, Prosper F, Nelson LJ, Banales JM, Martinez-Chantar ML, Marin JJG, Braconi C, Trautwein C, Corrales FJ, Cubero FJ, Berasain C, Fernandez-Barrena MG, Avila MA.
J Exp Clin Cancer Res
41 :
2022
183
11
Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma.
Silvestri M, Nghia Vu T, Nichetti F, Niger M, Di Cosimo S, De Braud F, Pruneri G, Pawitan Y, Calza S, Cappelletti V.
Cancer Med
12 :
2023
10156-10168
7
Preoperative immunological plasma markers TRAIL, CSF1 and TIE2 predict survival after resection for biliary tract cancer.
Jansson H, Cornillet M, Sun D, Filipovic I, Sturesson C, O'Rourke CJ, Andersen JB, Björkström NK, Sparrelid E.
Front Oncol
13 :
2023
1169537
3
Molecular profiling reveals potential targets in cholangiocarcinoma.
Liu D, Shi Y, Chen H, Nisar MA, Jabara N, Langwinski N, Mattson S, Nagaoka K, Bai X, Lu S, Huang CK.
World J Gastroenterol
29 :
2023
4053-4071
2
Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches.
Porreca V, Barbagallo C, Corbella E, Peres M, Stella M, Mignogna G, Maras B, Ragusa M, Mancone C.
Cancers (Basel)
16 :
2024
2889
2
